NORWOOD IMMUNOLOGY STARTS BMT CLINICAL TRIAL

Norwood Immunology has commenced Phase II clinical trial in cancer patients undergoing autologous (self-derived) bone marrow transplant (BMT).

The first of the 80 patients has been enrolled at University of Texas M.D. Anderson Cancer Center in Houston, and will be randomized to receive either Lupron Depot or placebo.

This double-blind, randomized Phase II clinical trial is being undertaken to determine whether there is enhanced immune recovery as a result of using the company's technology. It is being conducted in patients receiving standard of care high dose myeloablative chemotherapy therapy and autologous bone marrow transplant (also known as haematopoietic stem cell transplant) for the treatment of Hodgkin's disease, non-Hodgkin's lymphoma or multiple myeloma. Adult patients normally have very poor immune recovery following such chemotherapy treatment.